Glioblastoma Funding Rises as Nonprofits Drive Interest and Pharma Returns to the Table
After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma research is entering a new phase spurred by smarter trials, targeted funding and renewed interest from companies like Merck and Jazz Pharmaceuticals.Read more:
biospace.comBiotechnology